Vaxcyte Quarterly Balance Sheet
NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vaxcyte financial position
As of Jun 30, 2026, Vaxcyte reported total assets of $3.14 billion, down 5.1% from a year earlier against total liabilities of $380.2 million. Shareholders' equity stood at $2.76 billion, or 87.9% of assets. The company held $183.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 5.72, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Vaxcyte balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 183.19M | 260.84M | 173.96M | 281.08M | 306.74M | 346.85M | 387.88M | 1.05B | 518.67M | 611.51M | 397.45M | 545.13M |
| Short-Term Investments | 1.30B | 1.48B | 1.39B | 1.43B | 1.35B | 1.32B | 1.36B | 1.13B | 934.03M | 875.01M | 682.78M | 720.55M |
| Total Current Assets | 1.55B | 1.81B | 1.63B | 1.77B | 1.72B | 1.72B | 1.79B | 2.21B | 1.48B | 1.52B | 1.10B | 1.30B |
| Property, Plant & Equipment | 260.39M | 260.69M | 257.37M | 253.49M | 242.27M | 217.16M | 198.04M | 163.24M | 125.97M | 84.83M | 79.63M | 11.43M |
| Long-Term Investments | 1.02B | 1.00B | 881.66M | 959.26M | 1.17B | 1.28B | 1.39B | 1.09B | 399.24M | 413.25M | 162.68M | 168.56M |
| Total Assets | 3.14B | 3.35B | 3.00B | 3.17B | 3.31B | 3.38B | 3.51B | 3.56B | 2.09B | 2.09B | 1.41B | 1.50B |
| Accounts Payable | 100.92M | 63.06M | 70.90M | 48.96M | 31.41M | 20.51M | 48.45M | 18.22M | 10.47M | 21.72M | 14.59M | 15.70M |
| Total Current Liabilities | 271.28M | 242.08M | 205.75M | 200.05M | 154.49M | 97.00M | 140.18M | 123.79M | 82.85M | 87.10M | 145.34M | 85.56M |
| Total Liabilities | 380.21M | 352.29M | 317.21M | 278.72M | 234.03M | 178.08M | 205.50M | 142.11M | 101.14M | 107.32M | 167.45M | 93.34M |
| Shareholders' Equity | 2.76B | 3.00B | 2.69B | 2.89B | 3.07B | 3.20B | 3.31B | 3.42B | 1.99B | 1.98B | 1.24B | 1.40B |
| Retained Earnings | -2.76B | -2.48B | -2.15B | -1.91B | -1.70B | -1.53B | -1.39B | -1.25B | -1.15B | -1.02B | -924.39M | -743.59M |
| Net Cash (Debt) | 1.49B | 1.74B | 1.56B | 1.71B | 1.66B | 1.67B | 1.75B | 2.18B | 1.45B | 1.49B | 1.08B | 1.27B |
| Shares Outstanding | 144.79M | 144.31M | 131.06M | 130.03M | 129.82M | 128.94M | 124.89M | 124.43M | 110.58M | 108.76M | 95.36M | 95.10M |
This table shows 12 quarterly periods of Vaxcyte's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow PCVX's reporting calendar. What is a balance sheet?